Promise Clarifies NAD+ Classification Amid Federal Peptide Policy Review
Promise, operated by myPromise, LLC, today announced a clarification of how NAD+ is classified and prescribed, as federal officials review a proposed policy on compounding certain peptides. The announcement distinguishes NAD+, a coenzyme involved in cellular metabolism, from peptides and explains why the federal review does not itself change the regulatory status of compounded NAD+ injections. Promise is outlining the distinction to help...
Read more








